Previously, Pien Tze Huang released the 2020 annual performance forecast. During the period, the total operating income was 6.507 billion yuan, a year-on-year increase of 65,438+03.72%; The net profit attributable to the mother was 65.438+66.7 billion yuan, up by 265.438+0.27% year-on-year, and the net profit attributable to the mother was 65.438+0.665.438+300 million yuan, up by 65.438+0.9.22% year-on-year. Since the beginning of 2020, Pien Tze Huang has increased by 247.5%, and its market value has soared from more than 60 billion yuan to 200 billion yuan. Why is it so awesome?
Pien Tze Huang is a company mainly engaged in the production and sales of tablets, granules and other medical products and tourist commodities. The company's main business includes Chinese patent medicine manufacturing and drug circulation.
The core products of the company are Pien Tze Huang series, including Pien Tze Huang, Pien Tze Huang capsules, compound Pien Tze Huang buccal tablets, compound Pien Tze Huang ointment, compound Pien Tze Huang hemorrhoid ointment and other Pien Tze Huang series products.
Pien Tze Huang, a traditional precious Chinese patent medicine exclusively produced by the company, originated from the court, flourished in temples, spread among the people and developed in the contemporary era. Because of its unique and magical curative effect, it has formed an excellent reputation and has been praised as a "national treasure and famous medicine" by Chinese medicine circles at home and abroad.
Traditional production techniques have been listed in the national intangible cultural heritage list, and their formulas and techniques have been classified as top secret by China Administration of Traditional Chinese Medicine and State Secrecy Bureau, listed as national first-class protected varieties of traditional Chinese medicine, and rated as famous brand products of traditional Chinese medicine in China.
Some time ago, Hurun Research Institute released the Hurun Brand List in 2020, and Pien Tze Huang became the most valuable medical and health brand, and was selected as one of the top ten growth leading brands (the only brand selected in the medical and health industry), ranking first among the most valuable brands in Fujian and first in the medical and health industry.
It is reported that this is the eighth year that Pien Tze Huang has won the Hurun brand list, which is a world-renowned brand value list. The good news of Pien Tze Huang Pharmaceutical has spread frequently to Hurun brand list, which once again shows the brand strength of Pien Tze Huang, a famous national treasure medicinal material.
In addition to drug sales, the company actively builds a health industry of health, health care and health food, and its products extend to health care products, health food, specialty cosmetics and daily chemical products. Among them, the cream produced by the company is loved by many young women.
The formula is protected by the state and has the right to use the scarce raw material musk. Precious traditional Chinese medicine has laid the groundwork for the price increase. From 2004 to 2020, the retail price has been raised by 19 times, and the volume and price have not decreased, and the price increase has not yet touched the ceiling.
In recent years, the company has actively built a "one core and two wings" big health industry development strategy with traditional Chinese medicine and biopharmaceuticals as the core, health care drugs, health food, functional drinks, special cosmetics and daily chemical products as the wings, and drug circulation as the supplement. Committed to making Pien Tze Huang a first-class health brand in China.
Pien Tze Huang, as a high-end health care product, plays an outstanding role in protecting the liver and relieving alcoholism. Under the concept of healthy drinking, Pien Tze Huang is expected to achieve rapid growth with the help of high-end liquor. From the perspective of medicinal properties, Pien Tze Huang ranks first in the Chinese patent medicine market for liver diseases.
At present, the trend of population aging in China is accelerating, and the number of patients with chronic diseases such as diabetes, hypertension and uremia keeps increasing by 15% every year. These people need long-term medication and hemoperfusion dialysis, which will be the golden track in the next 20 years. Pien Tze Huang has some unique advantages in regulating chronic diseases and sub-health, and has a strong certainty in the future.
In addition, Pien Tze Huang is the only A-share company with absolute monopoly and absolute pricing power except Kweichow Moutai.
Coupled with excellent management and excellent financial data, the current valuation is reasonable and the market value is relatively cheap. Looking at the absolute monopoly of the gold track in the next 20 years, 10 10 is certain, even 20 times 10 is not an exaggeration. It is one of the few A shares that can be used for providing for the aged in the growing period.
Source author's great investment in research